Alnylam Pharmaceuticals
ALNY
#378
Rank
$60.52 B
Marketcap
$458.12
Share price
-1.55%
Change (1 day)
78.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of September 2025 : $2.72 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company has $2.72 Billion USD in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31$2.69 B10.46%
2023-12-31$2.43 B11.27%
2022-12-31$2.19 B-9.98%
2021-12-31$2.43 B29.94%
2020-12-31$1.87 B22.02%
2019-12-31$1.53 B41.69%
2018-12-31$1.08 B-35.87%
2017-12-31$1.69 B169.72%
2016-12-31$0.62 B-41.99%
2015-12-31$1.08 B55.09%
2014-12-31$0.69 B183.36%
2013-12-31$0.24 B100.2%
2012-12-31$0.12 B-16.11%
2011-12-31$0.14 B-37.2%
2010-12-31$0.23 B-17.15%
2009-12-31$0.28 B-34.62%
2008-12-31$0.43 B10.37%
2007-12-31$0.38 B79.48%
2006-12-31$0.21 B171.57%
2005-12-31$80 M73.74%
2004-12-31$46.04 M98.53%
2003-12-31$23.19 M49.85%
2002-12-31$15.47 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Arrowhead Pharmaceuticals
ARWR
$0.90 B-66.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
$8.44 B 209.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
$0.85 B-68.77%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
$0.41 B-84.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
$65.36 M-97.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$9.75 B 257.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$10.45 B 283.61%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
$2.20 B-19.14%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel